What is LL-37?
LL-37 is the only antimicrobial peptide encoded in the human cathelicidin gene family — a distinction that makes it unique among all peptides in this guide. Your body produces LL-37 naturally as part of innate immune defense, releasing it from neutrophils, epithelial cells, and keratinocytes at sites of infection and injury. It's your first-line antimicrobial response at mucosal surfaces, skin, and wounds — killing bacteria, fungi, and viruses directly while simultaneously signaling the immune system to mount a coordinated adaptive response.
The biohacker appeal is broad. LL-37 sits at the intersection of three applications that consistently attract sophisticated users: immune optimization, wound healing, and gut health. On immune optimization: LL-37 modulates both innate and adaptive immunity, similar in therapeutic scope to Thymosin Alpha-1 but through an entirely different mechanism. On wound healing: LL-37 promotes angiogenesis, keratinocyte migration, and tissue repair through pathways that complement BPC-157's mechanism. On gut health: LL-37 is produced by intestinal epithelial cells and plays a role in maintaining gut barrier integrity.
The clinical evidence is in earlier stages — Phase I/II trials for wound healing and respiratory applications — but the mechanistic literature is exceptionally deep. LL-37 has been studied intensively for 25+ years as a drug candidate for antibiotic-resistant infections and wound care. The challenge has been delivery: LL-37 is rapidly degraded by proteases, making stable formulation difficult. This is why it's still in trials rather than approved.
How it works
Direct Antimicrobial Action
LL-37 is a cationic, amphipathic peptide that disrupts bacterial cell membranes via electrostatic interaction. The positively charged peptide binds to the negatively charged bacterial membrane, inserts into the lipid bilayer, and forms pores or causes membrane dissolution. Effective against gram-positive bacteria (S. aureus, Streptococcus), gram-negative bacteria (E. coli, P. aeruginosa), fungi (Candida), and some viruses. Crucially, because the mechanism targets membrane composition rather than specific metabolic pathways, antibiotic resistance is less likely to develop against LL-37.
Immunomodulation and Wound Healing
LL-37 activates TLR signaling, promotes dendritic cell maturation, stimulates chemokine production, and modulates inflammatory NF-κB activation. For wound healing: it stimulates keratinocyte migration and proliferation (re-epithelialization), promotes angiogenesis via VEGF upregulation, activates fibroblast migration, and reduces biofilm formation. This mechanism complements BPC-157's FAK-paxillin and VEGFR2/eNOS mechanisms.
Gut Epithelial Function
LL-37 is constitutively produced by intestinal epithelial cells and is a key regulator of gut barrier integrity. It modulates gut microbiome composition, prevents pathogen translocation across the epithelial layer, and regulates gut immune responses. Deficiency in gut LL-37 is associated with increased gut permeability and inflammatory bowel conditions.
What the research shows
Wound healing activity of the human antimicrobial peptide LL-37
Ramos R et al.
In vitro and in a rat wound model, LL-37 accelerated wound closure and promoted angiogenesis and keratinocyte/fibroblast activity. Preclinical support for LL-37's re-epithelialization and angiogenic wound-healing role (not a human clinical trial).
View on PubMed →The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium
Heilborn JD, Nilsson MF, Kratz G et al.
In human skin wounds, hCAP18/LL-37 peaked around 48 hours after injury in inflammatory cells and migrating epithelium, then fell as the wound closed — while chronic ulcer edges showed little to none. Blocking LL-37 with antibody dose-dependently stalled re-epithelialization and abolished keratinocyte proliferation (Ki67) in an organ-cultured skin model. Foundational evidence that LL-37 does real repair work beyond killing microbes.
View on PubMed →A comprehensive summary of LL-37, the factotum human cathelicidin peptide
Vandamme D, Landuyt B, Luyten W, Schoofs L.
Review covering LL-37's antibacterial, antifungal and antiviral activity alongside its immunomodulatory roles, plus wound healing, angiogenesis, modulation of apoptosis, and emerging links to cancer biology. A solid one-stop reference for the breadth of LL-37 biology.
View on PubMed →What the community reports
Common misconceptions
"LL-37 replaces antibiotics."
LL-37 has broad-spectrum antimicrobial activity and low resistance-development risk. But it is not a replacement for conventional antibiotics in active serious infections — its clinical application is complement and prevention, not replacement. For serious infections requiring antibiotics, see a physician.
"LL-37 stimulates the immune system uniformly."
LL-37 modulates immune responses — it can both activate and dampen different aspects of immune activity depending on context. In autoimmune conditions, LL-37 can trigger flares — it's implicated in lupus and psoriasis pathology. Anyone with autoimmune conditions should not use LL-37 without specialist guidance.
"LL-37 is just like BPC-157 for wound healing."
Both promote wound healing but through different mechanisms. BPC-157 works via FAK-paxillin fibroblast migration and VEGFR2/eNOS angiogenesis. LL-37 works via keratinocyte migration, VEGF-mediated angiogenesis, and antimicrobial defense at the wound site. They're complementary, not redundant.
IMMUNE STACK
Thymosin Alpha-1 addresses adaptive immunity via T-cell maturation and dendritic cell enhancement. LL-37 addresses innate immunity via direct antimicrobial action and TLR-mediated immune coordination. For wound healing: BPC-157 provides complementary FAK-paxillin and VEGFR2 mechanisms.
Open PepperLedger to track your LL-37 protocol →
Free to join. No credit card. Ask the Researcher about your LL-37 protocol once you're in.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · completed · NCT02225366Intratumoral LL37 in metastatic melanoma
- ClinicalTrials.gov · unknown · NCT04098562Topical LL-37 cream for diabetic foot ulcers